Newly reported from the USA: Cell-Free DNA Test Has 83.1 Percent Sensitivity for Detection of CRC
A cell-free DNA (cfDNA) blood-based test has sensitivity of 83.1 percent for detection of colorectal cancer and specificity of 89.6 percent for any advanced neoplasia, according to a study published in the March 14 issue of the New England Journal of Medicine.
Daniel C. Chung, M.D., from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues examined the performance characteristics of a cfDNA blood-based test in a population eligible for colorectal cancer screening. The coprimary outcomes were sensitivity for colorectal cancer and specificity for advanced neoplasia relative to screening colonoscopy.
Source: Advances and More licensed by HealthDay
